BR9814370A - Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. - Google Patents

Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.

Info

Publication number
BR9814370A
BR9814370A BR9814370-0A BR9814370A BR9814370A BR 9814370 A BR9814370 A BR 9814370A BR 9814370 A BR9814370 A BR 9814370A BR 9814370 A BR9814370 A BR 9814370A
Authority
BR
Brazil
Prior art keywords
recombinant
fusion protein
protein
rhabdovirus
heterologous fusion
Prior art date
Application number
BR9814370-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michel A Whitt
Clinton S Robinson
Original Assignee
Univ Tennessee Research Corp A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Research Corp A filed Critical Univ Tennessee Research Corp A
Publication of BR9814370A publication Critical patent/BR9814370A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9814370-0A 1997-12-22 1998-12-22 Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. BR9814370A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6847297P 1997-12-22 1997-12-22
PCT/US1998/026084 WO1999032648A1 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein

Publications (1)

Publication Number Publication Date
BR9814370A true BR9814370A (pt) 2000-10-10

Family

ID=22082797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814370-0A BR9814370A (pt) 1997-12-22 1998-12-22 Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.

Country Status (14)

Country Link
US (2) US6497873B1 (https=)
EP (1) EP1040198B1 (https=)
JP (1) JP4544497B2 (https=)
AP (1) AP1968A (https=)
AT (1) ATE451466T1 (https=)
AU (2) AU752004B2 (https=)
BR (1) BR9814370A (https=)
CA (1) CA2316033A1 (https=)
DE (1) DE69841372D1 (https=)
IL (2) IL136905A0 (https=)
MX (1) MXPA00006184A (https=)
NZ (1) NZ505312A (https=)
OA (1) OA11432A (https=)
WO (1) WO1999032648A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148621A0 (en) * 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
WO2002072776A2 (en) * 2001-03-09 2002-09-19 The Regents Of The University Of California Cell culture system for synthesis of infectious hepatitis c virus
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
JP2007524363A (ja) 2003-03-27 2007-08-30 オタワ ヘルス リサーチ インスティチュート 変異体水疱性口内炎ウイルスおよびそれらの使用
KR20060017635A (ko) * 2003-06-05 2006-02-24 와이어쓰 홀딩스 코포레이션 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물
EP1633860A2 (en) 2003-06-09 2006-03-15 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
US8961951B2 (en) * 2007-07-06 2015-02-24 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US20100215691A1 (en) 2009-02-20 2010-08-26 Parks Christopher L Recombinant viral vectors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013158263A1 (en) 2012-04-18 2013-10-24 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
AU2018261637A1 (en) * 2017-05-03 2019-12-12 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
US11274141B2 (en) 2017-05-10 2022-03-15 Wellstat Immunotherapeutics, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
CN115768784A (zh) * 2020-02-06 2023-03-07 勃林格殷格翰动物保健有限公司 用于检测抗弹状病毒抗体的多肽
WO2023051607A1 (zh) * 2021-09-29 2023-04-06 上海行深生物科技有限公司 病毒培养方法

Also Published As

Publication number Publication date
EP1040198B1 (en) 2009-12-09
IL136905A (en) 2007-10-31
AU2002300207B2 (en) 2006-07-13
AP1968A (en) 2009-04-30
AU1905699A (en) 1999-07-12
US20030138457A1 (en) 2003-07-24
IL136905A0 (en) 2001-06-14
WO1999032648A1 (en) 1999-07-01
AP2000001852A0 (en) 2000-06-30
US6497873B1 (en) 2002-12-24
JP4544497B2 (ja) 2010-09-15
MXPA00006184A (es) 2003-02-11
EP1040198A1 (en) 2000-10-04
OA11432A (en) 2004-04-26
DE69841372D1 (de) 2010-01-21
AU752004B2 (en) 2002-09-05
NZ505312A (en) 2003-01-31
ATE451466T1 (de) 2009-12-15
CA2316033A1 (en) 1999-07-01
JP2001526901A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
BR9814370A (pt) Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.
CO2020001113A2 (es) Muteínas de interleucina 21 y métodos de tratamiento
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
DK382786D0 (da) Overfladeaktivt rekombinant-alveolarprotein
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
BR9816013A (pt) Proteìna de ligação de interleucina-18
ES545760A0 (es) Procedimiento para preparar peptidos liberadores de la hormona del crecimiento.
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
BR112022010321A2 (pt) Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase
AR013529A1 (es) Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DK0811068T3 (da) Humane DNase I varianter
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego
MX2024013887A (es) Composiciones que comprenden interleucina-33 truncada e interleucina-2

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements